One To Watch

Kelonia Therapeutics

Company Overview

A clinical-stage biotechnology company whose proprietary iGPS platform generates CAR-T cells inside the patient's body, eliminating ex vivo manufacturing and lymphodepletion — and whose lead program just posted a 100% response rate in multiple myeloma. Kelonia Therapeutics is developing in vivo genetic medicines designed to deliver the efficacy of cell therapy without the logistical and toxicity burden that has kept conventional CAR-T confined to specialist centers. The clinical results from its lead program, KLN-1010, caught the attention of Eli Lilly, which agreed in April 2026 to acquire the company for up to $7 billion.

Headquarters and Global Presence

Kelonia is headquartered in Boston, Massachusetts, operating as a privately held, venture-backed company since its 2022 public launch. Its acquisition by Eli Lilly, expected to close in the second half of 2026, will fold the company's platform and pipeline into Lilly's growing in vivo cell-therapy franchise.

Founding and History

Kelonia was co-founded by Michael Birnbaum, Ph.D. (MIT) and Michael Fischbach, Ph.D. (Stanford), drawing on their respective work in cell engineering and immunology, with early incubation and seed funding from Venrock. The company emerged from stealth on April 28, 2022, simultaneously announcing a $50 million Series A financing backed by Alta Partners, Horizons Ventures, and Venrock. Within four years of launch, the company had advanced a first-in-class lentiviral in vivo CAR-T program into the clinic, attracted two major pharma collaborations, and secured a landmark acquisition agreement.

Therapy Areas and Focus

Kelonia's primary focus is relapsed or refractory multiple myeloma, a disease where existing CAR-T therapies — despite strong efficacy — remain inaccessible to many patients due to manufacturing delays, bridging chemotherapy requirements, and limited treatment-center capacity. The iGPS platform is also designed to address genetic diseases and additional oncology indications beyond myeloma. The strategic logic is straightforward: if an off-the-shelf intravenous infusion can replicate or exceed the depth of response seen with manufactured cell therapies, the addressable patient population expands dramatically.

Technology Platforms and Modalities

The in vivo Gene Placement System, or iGPS, uses engineered lentiviral vector-like particles fitted with modified envelopes and tropism molecules to deliver genetic payloads selectively to T cells circulating inside the patient. A single intravenous dose programs those T cells to express a chimeric antigen receptor, generating functional CAR-T cells in vivo without any ex vivo culture step. Critically, the approach has so far been administered without lymphodepleting chemotherapy — the preconditioning regimen that carries its own toxicity burden and hospitalization requirements in standard CAR-T protocols. The same vector architecture is designed to be target-agnostic, making iGPS a platform for in vivo gene therapy beyond oncology.

Key Pipeline and Programs

KLN-1010 is Kelonia's lead candidate and the program that defined its clinical identity. It is a lentiviral in vivo gene therapy that instructs a patient's own T cells to express an anti-BCMA chimeric antigen receptor, targeting the B-cell maturation antigen found on malignant myeloma plasma cells. KLN-1010 is being evaluated in the Phase I inMMyCAR study in relapsed or refractory multiple myeloma. Updated data presented at ASCO on May 31, 2026, covering 18 dosed patients, showed a 100% overall response rate and MRD-negative bone marrow at one month in all evaluable patients; among the six patients with at least four months of follow-up, responses included four stringent complete responses and two very good partial responses. The earliest enrolled patient remained MRD-negative beyond 10 months. Cytokine release syndrome was observed in 16 of 18 patients, all Grade 1-2; one Grade 3 ICANS event resolved within three days, with no delayed neurotoxicity — all without any lymphodepleting preconditioning. Beyond KLN-1010, the iGPS platform underpins undisclosed in vivo CAR-T programs being developed in collaboration with Johnson & Johnson and Astellas Pharma against proprietary targets.

Recent Developments

The defining event of Kelonia's recent history is Eli Lilly's April 20, 2026, announcement of a definitive acquisition agreement: $3.25 billion upfront in cash plus up to $3.75 billion in milestone payments, for total potential consideration of $7.0 billion. The deal followed Lilly's February 2026 acquisition of Orna Therapeutics (up to $2.4 billion), reflecting a deliberate strategic build in in vivo cell therapy. Six weeks after the acquisition announcement, KLN-1010's Phase I inMMyCAR data at ASCO 2026 validated the rationale publicly — Lilly Oncology president Jacob Van Naarden described the 100% response rate in heavily pretreated patients without preconditioning as "nutty."

Key Personnel

Kevin Friedman, Ph.D., serves as Chief Executive Officer and co-founder of Kelonia; he held the dual role of President and Chief Scientific Officer at the company's 2022 launch before transitioning to CEO. Michael Birnbaum, Ph.D., co-founded Kelonia from his position as associate professor of biological engineering at MIT, where his lab focuses on the molecular basis of T-cell recognition. Michael Fischbach, Ph.D., the second scientific co-founder, is associate professor of bioengineering and medicine at Stanford, contributing expertise in immunology and host-microbe interactions to the platform's scientific foundation.

Strategic Partnerships

On November 5, 2025, Kelonia announced a strategic collaboration with Johnson & Johnson to discover and develop next-generation in vivo CAR-T therapies against undisclosed targets using the iGPS platform. Prior to that, in 2024, Astellas Pharma's subsidiary Xyphos entered a research and license agreement with Kelonia to develop novel in vivo immuno-oncology therapeutics against undisclosed targets. Both deals preceded and likely informed Lilly's decision to pursue outright acquisition, confirming broad pharma conviction in iGPS as a platform rather than a single-asset play.

FAQ Section

The price reflects platform value as much as KLN-1010 itself. Lilly is acquiring iGPS — a target-agnostic delivery system capable of generating CAR-T cells in vivo across multiple indications — at the precise moment the technology has produced Phase I human data compelling enough that Lilly's own oncology president called the results "nutty." The $3.75 billion in contingent milestones also means Lilly's full exposure is performance-gated, structuring the risk across development stages.

BCMA is clinically validated in myeloma — approved CAR-T products from Bristol Myers Squibb and Johnson & Johnson target it — but access is limited by weeks-long manufacturing timelines, the need for lymphodepleting chemotherapy, and specialist center requirements. KLN-1010 targets the same antigen via a single off-the-shelf intravenous infusion without preconditioning, meaning the competitive differentiator is not the target but the delivery modality and its accessibility implications. If durability holds, the commercial case is substantial.

iGPS uses engineered lentiviral vector-like particles — distinct from adeno-associated viral vectors or lipid nanoparticles — fitted with modified envelopes and tropism molecules to achieve selective T-cell targeting in vivo. The lentiviral backbone integrates into the genome, supporting stable and durable CAR expression, which is essential for sustained anti-tumor activity. Competitors pursuing in vivo CAR-T via mRNA-LNP platforms face the challenge of transient expression; Kelonia's integrating vector is designed to avoid that limitation.

The 100% overall response rate across 18 patients and universal MRD negativity at one month are striking for a Phase I dose-escalation study in relapsed or refractory myeloma — a heavily pretreated population. The caveat is that the dataset is small and follow-up is short: only six patients have reached four months of observation, and the earliest patient's MRD negativity at 10 months, while encouraging, is a single data point. The safety profile — all CRS Grade 1-2, one transient Grade 3 ICANS — is notably clean, but the critical question of response durability across the full cohort remains unanswered at this stage.

Beyond KLN-1010, Kelonia's disclosed pipeline is built around the iGPS platform's collaborations: one program with Johnson & Johnson and one with Astellas Pharma's Xyphos subsidiary, both targeting undisclosed antigens for undisclosed indications. The company has also indicated that iGPS is applicable to genetic diseases beyond oncology, suggesting the platform's longer-term scope extends well beyond hematologic malignancies. Under Lilly's ownership, pipeline expansion decisions will reflect Lilly's broader therapeutic strategy.

Kelonia is early clinical-stage — KLN-1010 is in Phase I dose escalation — with the company's value currently resting on platform conviction and early human proof-of-concept rather than late-stage assets. The immediate clinical priority is expanding the inMMyCAR dataset to establish durability data across a larger cohort and confirm the safety profile at higher dose levels. Post-acquisition close in H2 2026, Lilly will determine the speed and scope of Phase II/III advancement for KLN-1010 and the pace at which iGPS is deployed across additional targets.

The principal watchpoints for Kelonia under Lilly's forthcoming ownership are:

Durability data from inMMyCAR: whether MRD negativity holds beyond 12 months across a larger cohort is the make-or-break clinical question.
Regulatory close of the Lilly acquisition in H2 2026 and any conditions attached to the transaction.
Dose-escalation safety signals: Grade 3 ICANS appeared once at current doses; higher doses could alter the toxicity profile.
Platform versatility: whether iGPS demonstrates clean in vivo T-cell targeting across additional antigens in the J&J and Astellas collaborations.
Competitive pressure from other in vivo CAR-T programs (including mRNA-LNP approaches) that could erode first-mover advantage if durability proves inferior.

Want to Update your Company's Profile?